Aims and objectives of this presentation
The session is focused on prostate cancer screening and early detection.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

The STHLM3 model improves prostate cancer testing in men 50-69 years - further health economic and clinic evaluation
By: Grönberg H.1, Adolfsson J.2, Aly M.1, Nordström T.1, Wiklund P.3, Brandberg Y.4, Thompson J.5, Wiklund F.1, Lindberg J.1, Clements M.1, Egevad L.4, Eklund M.1
Institutes: Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden, Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, Karolinska Institutet, Dept. of Oncology–Pathology, Stockholm, Sweden, Karolinska Institutet, Biobank, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

18-year follow up of the Gothenburg randomized population-based prostate cancer screening trial
By: Arnsrud Godtman R.1, Carlsson S.1, Grenabo Bergdahl A.1, Holmberg E.2, Stranne J.1, Lilja H.3, Hugosson J.1
Institutes: Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg, Dept. of Oncology, Gothenburg, Sweden, Memorial Sloan-Kettering Cancer Center/Nuffield Dept. of Surgical Sciences/Lund University Hospital, Dept. of Laboratory Medicine, Surgery (Urology), and Medicine (GU Oncology), Malmö, Sweden

Correlation between stage shift and differences in mortality between the two study arms of the ERSPC
By: Roobol M.J.1, Auvinen A.2, Carlsson S.V.3, Kwiatkowski M.4, Denis L.J.5, Zappa M.6, Paez A.7, Hugosson J.8, Moss S.M.9, Bokhorst L.P.1
Institutes: Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, University of Tampere, School of Medicine, Tampere, Finland, Sahlgrenska Academy At University of Gothenburg/Memorial Sloan-Kettering Cancer Center, Dept. of Urology, Gothenburg, Sweden, Kantonsspitale Aarau, Dept. of Urology, Aarau, Switzerland, Europa Uomo, Antwerp, Belgium, ISPO, Unit of Clinical and Descriptive Epidemiology, Florence, Italy, Hospital Universitario De Fuenlabrada, Dept. of Urology, Madrid, Spain, Sahlgrenska Academy At University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, Centre For Cancer Prevention, Queen Mary University of London, Cancer Prevention, London, United Kingdom

The association between family history and prostate-specific antigen from a large group of 45-year old men embarking on prostate cancer screening: Results from the PROBASE trial
By: Herkommer K.1, Laenger N.1, Klokert T.1, Ankerst D.2, Grill S.2, Schulwitz H.1, Albers P.3, Arsov C.3, Hadaschik B.4, Hohenfellner M.4, Kuczyk M.5, Imkamp F.5, Gschwend J.1
Institutes: Technical University of Munich, Dept. of Urology, Munich, Germany, Technical University of Munich, Dept. of Mathematics, Munich, Germany, University Dusseldorf, Medical
Poster Session 08

Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations
Institutes: Brigham and Women's Hospital, Division of Urology and Center For Surgery and Public Health, Boston, United States of America, Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America

The impact of 2012 United States Preventive Services Task Force (USPSTF) panel update on PSA screening practice: A nationwide, and state-by-state level analyses
By: Abdollah F., Dalela D., Sood A., Meyer C., Sun M., Trinh Q.D., Menon M., Sammon J.
Institutes: Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, Henry Ford Hospital, Dept. of Urology, Detroit, United States of America

Swiss prostate-check: A population based risk-calculator for next generation prostate cancer screening
By: Kwiatkowski M., Wyler S., Praise L., Möltgen T., Huber A., Grobholz R., Manka L., Seifert B., Randazzo M., Recker F.
Institutes: Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany, University of Zurich, Institute for Biostatistics, Zürich, Switzerland, University of Zurich, Dept. of Urology, Zürich, Switzerland

A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer
Institutes: Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America

Informed decision-making for prostate-specific antigen screening
Institutes: Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America

Detection of asymptomatic locally advanced and high-risk prostate cancer through PSA testing: Clinical outcomes in men excluded from the ProtecT Trial
Institutes: Cambridge University and Cambridge University Hospitals NHS Trust, Surgical Academic Urological Grou, Dept. of Surgery, Cambridge, United Kingdom, Cambridge University and Cambridge University Hospitals NHS Trust, Cambridge, Uk, Dept. of Urology, Cambridge, United Kingdom, National Cancer Registration Service - Eastern Office, Dept. of Public Health, Cambridge, United Kingdom, Cancer Research UK Cambridge Institute, Dept. of Urology, Cambridge, United Kingdom, Academic Urology Unit, Royal Hallamshire Hospital, Dept. of Surgery, Sheffield, United Kingdom, School of Social and Community Medicine, Dept. of Urology, Bristol, United Kingdom, Nuffield Department of Surgical Sciences, Dept. of Surgery, Oxford,
Comorbidities and concomitant medications at time of diagnosis of prostate cancer: Data from the PROS-IT CNR study

By: Gacci M.¹, Artibani W.², Bassi P.³, Bertoni F.⁴, Bracarda S.⁵, Conti G.⁶, Corvò R.⁷, Grazioti P.⁸, Maggi S.⁹, Magrini S.M.¹⁰, Maurizi Enrici R.¹¹, Mirone V.¹², Montironi R.¹³, Muto G.¹⁴, Noale M.¹⁵, Pecoraro S.¹⁶, Porreca A.¹⁷, Ricardi U.¹⁷, Tubaro A.¹⁸, Zagonel V.¹⁹, Zattoni F.²⁰

Institutes: University of Florence, Dept. of Urology, Florence, Italy, Azienda Ospedaliera Universitaria Integrita and University of Verona, Dept. of Urology and Oncological and Surgical Sciences, Verona, Italy, University of Rome La Cattolica, Dept. of Urology, Rome, Italy, Italian Association For Radiation Oncology, Referent For The Prostate Group of AIRO, Rome, Italy, Ospedale San Donato, Azienda USL8, Dept. of Medical Oncology, Arezzo, Italy, St. Anna Hospital, Dept. of Urology, Como, Italy, AOU IRCCS San Martino – IST National Cancer Research Institute and University, Dept. of Radiation Oncology, Genoa, Italy, Ospedale S. Giuseppe, Dept. of Urology, Milan, Italy, CNR, Neuroscience Institute, Dept. of Aging Branch, Padua, Italy, University of Brescia and Spedali Civili Hospital, Dept. of Radiation Oncology Unit, Brescia, Italy, University “La Sapienza”, Dept. of Radiation Oncology, Rome, Italy, University Federico II, Dept. of Urology, Naples, Italy, Polytechnic University of The Marche Region, Section of Pathological Anatomy, Ancona, Italy, Campus Bio-Medico University of Rome, Dept. of Urology, Rome, Italy, Malzoni Center, Dept. of Nephrourology, Avellino, Italy, Abano Terme General Hospital, Dept. of Urology, Padua, Italy, University of Turin, Dept. of Oncology, Radiation Oncology, Turin, Italy, Sant’Andrea Hospital, Sapienza University of Rome, Dept. of Urology, Rome, Italy, Istituto Oncologico Veneto IOV – IRCCS, Dept. of Medical Oncology, Padua, Italy, University of Padua, Dept. of Urology, Padua, Italy

---

Repeat prostate-specific antigen (PSA) tests before biopsy decisions: Results from the STHLM3 diagnostic trial

By: Nordström T.¹, Adolfsson J.², Grönberg H.¹, Eklund M.¹

Institutes: Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden

Summary and context

S.V. Carlsson, New York (US)